A common marker of affect recognition dysfunction in the FTD spectrum of disorders
- PMID: 39632486
- PMCID: PMC11617592
- DOI: 10.1111/ene.16578
A common marker of affect recognition dysfunction in the FTD spectrum of disorders
Abstract
Background: Poor affect recognition is an early sign of frontotemporal dementia (FTD). Here, we applied the abbreviated version of the Comprehensive Affect Testing System (CATS-A) battery to Italian FTD cases and healthy controls (HC) to provide cut-offs of emotional dysfunction in the whole group and in different FTD clinical syndromes.
Methods: One hundred thirty-nine FTD patients (60 behavioural variant [bvFTD],13 semantic behavioural variant of FTD [sbvFTD], 28 progressive supranuclear palsy [PSP], 21 semantic [svPPA] and 17 nonfluent [nfvPPA] variants of primary progressive aphasia) and 116 HC were administered the CATS-A, yielding an Affective Recognition Quotient (ARQ), which was used as outcome measure. Age- and education-adjusted, regression-based norms were derived in HC. In patients, the ARQ was assessed for its internal reliability, factorial validity and construct validity by testing its association with another social cognition paradigm, the Story-Based Empath Task (SET). The diagnostic accuracy of the ARQ in discriminating patients from HC, genetic cases from HC and patient groups among each other was tested via ROC analyses.
Results: In the whole FTD cohort, CATS-A proved to be underpinned by a mono-component factor (51.1%) and was internally consistent (McDonald's ω = 0.76). Moreover, the ARQ converged with the SET (r(122) = 0.50; p < 0.001) and optimally discriminated HC from both the whole cohort (AUC = 0.89) and each clinical syndrome (AUC range: 0.83-0.92). Conversely, CATS-A subtests were able to distinguish patient groups.
Conclusions: The ARQ score from the CATS-A distinguishes FTD clinical syndromes from HC with high accuracy, making it an excellent tool for immediate use in clinical practice.
Keywords: CATS‐A; FTD; comprehensive affect testing system; emotion recognition; frontotemporal degeneration.
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Conflict of interest statement
E. Canu has received research supports from the Italian Ministry of Health. F. Verde is an associate editor for Journal of Alzheimer's Disease. N. Ticozzi received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA, and he is an associate editor for Frontiers in Aging Neuroscience. V. Silani received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, Amylyx Pharmaceuticals, Biogen and Zambon Biotech SA, he receives or has received research supports from the Italian Ministry of Health, AriSLA and E‐Rare Joint Transnational Call, and he is in the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy. B. Poletti received compensation for consulting services and/or speaking activities from Liquidweb S.r.l, and she is an associate editor for Frontiers in Neuroscience. M. Filippi is Editor‐in‐Chief of the Journal of Neurology and an associate editor of Human Brain Mapping, Neurological Sciences, and Radiology; he received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck‐Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and TEVA, participated in Advisory Boards for Alexion, Biogen, Bristol‐Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi‐Aventis, Sanofi‐Genzyme and Takeda, and done scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol‐Myers Squibb, Lilly, Novartis and Sanofi‐Genzyme; he receives research support from Biogen Idec, Merck‐Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research and Fondazione Italiana Sclerosi Multipla. F. Agosta is an associate editor of NeuroImage: Clinical, has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon and Eli Lilly, and received or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme—Neurodegenerative Disease Research (JPND) and Foundation Research on Alzheimer Disease (France). V. Castelnovo, E.N. Aiello, G. de Luca, E. Sibilla, F. Freri, C. Tripodi, E.G. Spinelli, G. Cecchetti, G. Magnani, F. Caso, P. Caroppo, S. Prioni, C. Villa, L. Tremolizzo, I. Appollonio, V. Sturm, K.P. Rankin and M.L. Gorno‐Tempini have nothing to disclose.
Figures

Similar articles
-
How to detect affect recognition alterations in amyotrophic lateral sclerosis.J Neurol. 2024 Nov;271(11):7208-7221. doi: 10.1007/s00415-024-12686-6. Epub 2024 Sep 17. J Neurol. 2024. PMID: 39287680
-
Intracortical diffusion tensor imaging signature of microstructural changes in frontotemporal lobar degeneration.Alzheimers Res Ther. 2021 Oct 22;13(1):180. doi: 10.1186/s13195-021-00914-4. Alzheimers Res Ther. 2021. PMID: 34686217 Free PMC article.
-
The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.Parkinsonism Relat Disord. 2015 Oct;21(10):1264-8. doi: 10.1016/j.parkreldis.2015.08.006. Epub 2015 Aug 11. Parkinsonism Relat Disord. 2015. PMID: 26324212
-
Neuropsychiatric Aspects of Frontotemporal Dementia.Psychiatr Clin North Am. 2020 Jun;43(2):345-360. doi: 10.1016/j.psc.2020.02.005. Epub 2020 Apr 8. Psychiatr Clin North Am. 2020. PMID: 32439026 Review.
-
Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches.Crit Rev Clin Lab Sci. 2023 May;60(3):171-188. doi: 10.1080/10408363.2022.2150833. Epub 2022 Dec 12. Crit Rev Clin Lab Sci. 2023. PMID: 36510705 Review.
References
-
- Magno MA, Canu E, Agosta F, Filippi M. Measuring social cognition in frontotemporal lobar degeneration: a clinical approach. J Neurol. 2022;269:2227‐2244. - PubMed
-
- Haxby JV, Hoffman EA, Gobbini MI. The distributed human neural system for face perception. Trends Cogn Sci. 2000;4:223‐233. - PubMed
-
- Morton J, Johnson MH. CONSPEC and CONLERN: a two‐process theory of infant face recognition. Psychol Rev. 1991;98:164‐181. - PubMed
-
- Ekman P, Friesen WV. Constants across cultures in the face and emotion. J Pers Soc Psychol. 1971;17:124‐129. - PubMed
-
- Delbeuck X, Pollet M, Pasquier F, Bombois S, Moroni C. The clinical value of the faux pas test for diagnosing behavioral‐variant frontotemporal dementia. J Geriatr Psychiatry Neurol. 2022;35:62‐65. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous